Nicholas Piramal India (NPIL), a pharmaceutical company, operates in the therapeutic segments of anti-bacterials, cardiovasculars, anti-diabetics, nutritionals, central nervous system and gastro-intestinals. In addition, it has a presence in the OTC segment through its various joint ventures and alliances. Nicholas Piramal`s primary brands Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint account for 67 per cent of the company`s turnover, whereas its secondary brands such as Paraxin, Flagyl and Omnatax account for 24 per cent of its turnover. The secondary brands, however, are the company`s cash cows. NPIL has inked joint ventures with Allergan (eye-care), Ambalal Sarabhai (distribution of ethical products), Boots (OTC products), Shree Dhootapapeshwar (ayurvedic medicines), Laporte (food additives), Bupa (Wellspring Hospital), Charak Pharmaceuticals (ayurvedic) and Solumiks Pharma (ayurvedic). It also has access to newly patented products coming out of the research pipeline of F.Hoffmann-La Roche and Boehringer Mannheim. The company has four subsidiaries namely Gujarat Glass Ltd, Ceylon Glass Co. Ltd, Drs.Tribedi & Roy Diagnostic Laboratories and Dr Phadke Pathalogy Laboratory & Infertility Centre. In December 2000, NPIL acquired 60 per cent stake in Rhone Poulenc India. The company`s manufacturing actrivities are well supported by active research and development, a phenomenon which has shown a healthy growth in the past five years. It has set up an R&D facility called the `Quest Institute of Life Sciences` in Mumbai that focusses on process development.
Piramal Healthcare Share Market Live Price & Charts
Nicholas Piramal India (NPIL), a pharmaceutical company, operates in the therapeutic segments of anti-bacterials, cardiovasculars, anti-diabetics, nutritionals, central nervous system and gastro-intestinals. In addition, it has a presence in the OTC segment through its various joint ventures and alliances. Nicholas Piramal`s primary brands Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint account for 67 per cent of the company`s turnover, whereas its secondary brands such as Paraxin, Flagyl and Omnatax account for 24 per cent of its turnover. The secondary brands, however, are the company`s cash cows. NPIL has inked joint ventures with Allergan (eye-care), Ambalal Sarabhai (distribution of ethical products), Boots (OTC products), Shree Dhootapapeshwar (ayurvedic medicines), Laporte (food additives), Bupa (Wellspring Hospital), Charak Pharmaceuticals (ayurvedic) and Solumiks Pharma (ayurvedic). It also has access to newly patented products coming out of the research pipeline of F.Hoffmann-La Roche and Boehringer Mannheim. The company has four subsidiaries namely Gujarat Glass Ltd, Ceylon Glass Co. Ltd, Drs.Tribedi & Roy Diagnostic Laboratories and Dr Phadke Pathalogy Laboratory & Infertility Centre. In December 2000, NPIL acquired 60 per cent stake in Rhone Poulenc India. The company`s manufacturing actrivities are well supported by active research and development, a phenomenon which has shown a healthy growth in the past five years. It has set up an R&D facility called the `Quest Institute of Life Sciences` in Mumbai that focusses on process development.
Related Posts
Nifty / Bank Nifty Option Tip
Looking to trade intraday Nifty or Bank Nifty options? Our Nifty / Bank Nifty Option Tip shares trading calls with a defined entry, target and stop loss, so you know your risk before you trade. It suits traders who follow the market on a trading screen as well as those who place orders through their broker or by phone. Click on Image or Post Title to Read More.
Latest Video Reviews by Clients
Watch video reviews recorded by our clients about their experience with Indian-Share-Tips.com services, including the Nifty / Bank Nifty Option Tip and Delivery Tip. Click on Image or Post Title to Read More.
Awards and Recognition
See the awards and recognition Indian-Share-Tips.com has received over the years for its work in stock market research and investor education. Click on Image or Post Title to Read More.

